Skip to contentpdufa.bio

Descartes-08 (mRNA CAR-T)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Descartes-08 (mRNA CAR-T) is a Cartesian Therapeutics, Inc. program in myasthenia gravis. Its next catalyst is a Readout in Q1 2027.

RNAC catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Myasthenia gravis; Myositis; Pediatric autoimmune diseases incl. juvenile dermatomyositis. Sponsor: Cartesian Therapeutics, Inc. (RNAC). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027RNACReadout · Q2 2027RNACReadout · Q2 2027RNAC

Questions

When is Descartes-08 (mRNA CAR-T)'s next FDA decision or readout?

The next tracked catalyst for Descartes-08 (mRNA CAR-T) is a Readout in Q1 2027.

What happened at Descartes-08 (mRNA CAR-T)'s most recent FDA decision?

No FDA decision for Descartes-08 (mRNA CAR-T) is in our archive yet.

What is Descartes-08 (mRNA CAR-T) used for?

In our records Descartes-08 (mRNA CAR-T) is under review or in development for Myasthenia gravis; Myositis.

Who makes Descartes-08 (mRNA CAR-T)?

Cartesian Therapeutics, Inc. (RNAC).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.